Consensus CSL Limited

Stocks

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 11:42:23 10/08/2026 am IST			5-day change	1st Jan Change
134.47 ^AUD	+1.72%		+9.27%	-22.11%

08:22am	ASX Midday Sector Update: Healthcare Stocks Advance, Financial Sector Struggles	MT
07/08	ASX Midday Sector Update: Energy Stocks Advance, Healthcare Sector Struggles	MT

Evolution of the Average Target: CSL Limited

Evolution of the Target Price: CSL Limited

Changes in Analyst Recommendations: CSL Limited

b8102ea261cbd953f3b5a0.lY7EnnuWOS4e61iw8lGrLCZ5wyYFc5l5ZkSk4MAlEbo.1ueLyE6gUGVNhmH2mxrCS1Is9hcoOa0aDCqctI8cc_bEwY7_MfgPenS9bA~ea147ead6ba646d3df488f25865dea30

Analysts' recommendations: CSL Limited

25/06	CSL, Plasma Industry Could Continue to Grow Strongly for Considerable Period, Jefferies Says	MT
12/05	CSL's Fiscal-Year Earnings Guidance Downgrade Not Surprising, Jefferies Says	MT
20/03	CSL's Business Not Threatened by CIDP Therapy Competition, Says Jefferies	MT
02/03	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
11/02	CSL's Fiscal H1 EBIT Boosted by Cost Reductions, Jarden Says	MT
09/12	CSL's China Albumin Sale to Improve in Fiscal H2 2026, Says Jefferies	MT
11/11	CSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies	MT
07/11	CSL Expected to See Potential Medium-Term Earnings Upside, Says Jefferies	MT
07/11	CSL's Horizon 2 Approach to 'Significantly' Boost Margins, Earnings, Jarden Says	MT
29/25/29	Jarden Research Adjusts CSL's Price Target to AU$287.14 from AU$304.17, Keeps at Overweight	MT
29/25/29	CSL Faces Macroeconomic Challenges, Will Take Time to Rerate, Says Jefferies, Shares Down 3%	MT
28/25/28	Canaccord Genuity Upgrades CSL to Buy from Hold; Price Target is AU$225	MT
28/25/28	CSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says	MT
02/25/02	CSL to Benefit From Immunoglobin Sales Growth, Says Jefferies	MT
01/25/01	Carlisle Faces Downgrade From Loop Capital; Shares Fall	MT
11/25/11	CSL Shares Fall Amid Target Price Cut by Morgans Financial	MT
10/25/10	Morgans Financial Upgrades CSL to Buy from Add; Price Target is AU$303.70	MT
25/24/25	CSL's R&D Day "Uninspiring," Jarden Research Says	MT
09/24/09	CSL 'Strong Franchise in Medium Term' Amid Higher Fiscal 2024 Earnings, Jefferies Says	MT
05/24/05	Carlisle Expected to Show Solid Growth, Margin Expansion, Oppenheimer Says	MT
14/24/14	Jarden Research Adjusts CSL's Price Target to AU$329.62 From AU$305.34, Keeps at Overweight	MT
06/24/06	Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight	MT
14/24/14	Jarden Research CSL’s Price Target to AU$296.02 From AU$298.57, Keeps at Overweight	MT
13/24/13	Jarden Research Adjusts CSL’s Price Target to AU$298.57 From AU$316.16, Keeps at Overweight	MT
02/22/02	Arcturus Therapeutics Shares Rise 31% After Vaccine Collaboration	DJ

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CSL LIMITED					+3.7%
	REGENERON PHARMACEUTICALS, INC.					+6.27%
	SAMSUNG BIOLOGICS CO.,LTD.					+26.96%
	UCB					+28.24%
	BIOGEN INC.					+13.17%
	INCYTE CORPORATION					+3.65%
	MODERNA, INC.					-14.07%
	INNOVENT BIOLOGICS, INC.					+24.77%
	SWEDISH ORPHAN BIOVITRUM AB					+9.79%
	BRIDGEBIO PHARMA, INC.					+25.7%
	Average					+12.82%
	Weighted average by Cap.					+13.17%